Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Davis, Alicia M ^a   Chabolla, Bryan J ^a   Newcomb, Laura L ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Influenza; NP; RdRP; Resistance

Indexed keywords

ANTIVIRUS AGENT; HEAT SHOCK PROTEIN 27; RIBONUCLEOPROTEIN; RIBONUCLEOTIDE; RNA DIRECTED RNA POLYMERASE; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; DRUG COMBINATION; HUMAN; INFLUENZA A; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H7N9; LIFE CYCLE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TRANSCRIPTION INITIATION; VIRUS STRAIN; COMMUNICABLE DISEASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; GENE EXPRESSION REGULATION, VIRAL; HUMANS; INFLUENZA A VIRUS; RIBONUCLEOPROTEINS; VIRAL PROTEINS;

EID: 84907915756     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-167     Document Type: Review

References (98)

1. The origin of the 1918 pandemic influenza virus: a continuing enigma. Reid AH, Taubenberger JK, J Gen Virol 2003 84 2285 2292 10.1099/vir.0.19302-0 12917448
2. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Neumann G, Noda T, Kawaoka Y, Nature 2009 459 931 939 10.1038/nature08157 19525932
3. Influenza viruses and mRNA splicing: doing more with less. Dubois J, Terrier O, Rosa-Calatrava M, mBio 2014 5 00070 14 24825008
4. A novel influenza A virus mitochondrial protein that induces cell death. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW, Nat Med 2001 7 1306 1312 10.1038/nm1201-1306 11726970
5. A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, Howard W, Anderson EC, Barclay WS, Digard P, J Virol 2009 83 8021 8031 10.1128/JVI.00826-09 19494001
6. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Jagger BW, Wise H, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL, Schartzman LM, Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins JF, Firth AE, Taubenberger JK, Digard P, Science 2012 337 199 204 10.1126/science.1222213 22745253
7. Identification of novel influenza A virus proteins translated from PA mRNA. Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y, J Virol 2012 87 2455 2462 23236060
8. Influenza virus M2protein has ion channel activity. Pinto LH, Holsinger LJ, Lamb RA, Cell 1992 69 517 528 10.1016/0092-8674(92)90452-I 1374685
9. The molecular basis of the specific anti-influenza action of amantadine. Hay AJ, Wolstenholm AJ, Skehel JJ, Smith MH, EMBO J 1985 4 3021 3024 4065098
10. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Jing X, Ma C, Ohigashi Y, Oliveria FA, Jardetzky TS, Pinto LH, Lamb RA, Proc Natl Acad Sci U S A 2008 105 10967 10972 10.1073/pnas.0804958105 18669647
11. Active influenza virus neuraminidase is expressed in monkey cells from cDNA cloned in simian virus 40 vectors. Davis AR, Bos TJ, Nayak DP, Proc Natl Acad Sci U S A 1983 80 3976 3980 10.1073/pnas.80.13.3976 6306656
12. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H, Virology 1974 58 457 463 10.1016/0042-6822(74)90080-4 4362431
13. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoracetylneuraminic acid (FANA). Palese P, Compans RW, Virology 1974 59 490 498 10.1016/0042-6822(74)90458-9 4364826
14. Influenza A virus M2 ion channel protein: a structure-function analysis. Holsinger LJ, Nichani D, Pinto LH, Lamb RA, J Virol 1984 68 1551 1563
15. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Abed Y, Goyette N, Boivin G, Antimicrob Agents Chemother 2005 49 556 559 10.1128/AAC.49.2.556-559.2005 15673732
16. Centers for Disease Control and Prevention. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5929a2.htm
17. Emergence of adamantane-resistant influenza A (H3N2) viruses in Hong Kong between 1997 and 2006. Tang JW, Ngai KL, Wong JC, Lam WY, Chan PK, J Med Virol 2008 80 895 901 10.1002/jmv.21155 18360910
18. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, Yao H, Wo J, Fang Q, Cui D, Li Y, Yao X, Zhang Y, Wu H, Zheng S, Diao H, Xia S, Zhang Y, Chan KH, Tsoi HW, Teng JL, Song W, Wang P, Lau SY, Zheng M, Chan JF, To KK, Chen H, Li L, Yuen KY, Lancet 2013 381 1916 1925 10.1016/S0140-6736(13)60903-4 23623390
19. Centers for Disease Control and Prevention. http://www.cdc.gov/flu/pastseasons/0910season.htm
20. Centers for Disease Control and Prevention. http://www.cdc.gov/flu/about/qa/antiviralresistance.htm
21. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV, Antimicrob Agents Chemother 2010 54 1102 1110 10.1128/AAC.01417-09 20028826
22. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Pizzorno A, Abed Y, Bouhy X, Beaulieu É Mallett C, Russell R, Boivin G, Antimicrob Agents Chemother 2012 56 1208 1214 10.1128/AAC.05994-11 22203589
23. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. van der Vries E, Kroeze EJV, Stittelaar KJ, Linster M, Van der Linden A, Schrauwen EJ, Leijten LM, van Amoerogen G, Schutten M, Kuiken T, Osterhaus AD, Fouchier RA, Boucher CA, Herfst S, PLoS pathogens 2011 7 1002276 10.1371/journal.ppat.1002276 21980293
24. Emergenge of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. Baz M, Abed Y, Papenbug J, Bouhy X, Hamelin ME, Boivin G, Engl J Med 2009 361 2296 2297 10.1056/NEJMc0910060
25. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y, Lancet 2004 364 759 765 10.1016/S0140-6736(04)16934-1 15337401
26. WHO. http://www.who.int/influenza/human-animal-interface/avian-influenza/h5n1-research/faqs/en/
27. Human infection with a novel avian-origin influenza A (H7N9) virus. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Yang L, Guo J, Dong J, Li Q, Dong L, et al. N Engl J Med 2013 368 1888 1897 10.1056/NEJMoa1304459 23577628
28. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe ER, Krammer F, Solòrzano A, Carcia-Sastre A, Palese P, Bouvier NM, Nat Commun 2013 4 2854 24326875
29. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG, Antivir Res 2007 73 228 231 10.1016/j.antiviral.2006.10.004 17112602
30. A unique cap (m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Plotch SJ, Bouloy M, Ulmanen I, Krug RM, Cell 1981 23 847 858 10.1016/0092-8674(81)90449-9 6261960
31. Crystral structure of an avian influenza polymerase PANreveals an endonuclease active site. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, He X, Lv Z, Ge R, Li X, Deng T, Fodor E, Rao Z, Liu Y, Nature 2009 458 909 913 10.1038/nature07720 19194458
32. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ, Baudin F, Cusack S, Ruigrok RW, Nature 2009 458 914 918 10.1038/nature07745 19194459
33. The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. Li ML, Rao P, Krug RM, EMBO J 2001 20 2078 2086 10.1093/emboj/20.8.2078 11296240
34. Direct evidence that the poly (A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template. Poon LL, Pritlove DC, Fodor E, Brownlee GG, J Virol 1999 73 3473 3476 10074205
35. Influenza Virus RNA Replication In Vitro: Synthesis of Viral Template RNAs and Virion RNAs in the Absence of an Added Primer. Shapiro GI, Krug RM, J Virol 1988 62 2285 2290 2453679
36. Genetic trans-complementation establishes a new model for influenza virus RNA transcription and replication. Jorba N, Coloma R, Ortín J, PLoS pathogens 2009 5 1000462 10.1371/journal.ppat.1000462 19478885
37. Transcription antitermination during influenza viral template RNA synthesis requires the nucleocapsid protein and the absence of a 5'capped end. Beaton AR, Krug RM, Proc Natl Acad Sci USA 1986 83 6282 6286 10.1073/pnas.83.17.6282 3462695
38. RNA Polymerase of Influenza Virus: Role of NP in RNA Chain Elongation. Honda A, Ueda K, Nagata K, Ishihama A, J Biochem 1988 104 1021 1026 3243763
39. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Ye Q, Krug RM, Tao YJ, Nature 2006 444 1078 1082 10.1038/nature05379 17151603
40. Biochemical and structural evidence in support of a coherent model for the formation of the double-helical influenza A virus ribonucleoprotein. Ye Q, Guu TS, Mata DA, Kuo RL, Smith B, Krug RM, Tao YJ, mBio 2012 4 00467 12 23269829
41. Identification of influenza A nucleoprotein as an antiviral target. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY, Nat Biotechnol 2010 28 600 605 10.1038/nbt.1638 20512121
42. E339. R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Shen YF, Chen Y, Chu SY, Lin MI, Hsu HT, Wu PY, Wu CJ, Liu HW, Lin FY, Lin G, Hsu PH, Yang AS, Cheng YS, Wu YT, Wong CH, Tsai MD, Proc Nat Acad Sci USA 2011 108 16515 16520 10.1073/pnas.1113107108 21930946
43. Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. Biswas SK, Boutz PL, Nayak DP, J Virol 1988 72 5493 5501
44. Association of influenza virus NP and M1 proteins with cellular cytoskeletal elements in influenza virus-infected cells. Avalos RT, Yu Z, Nayak DP, J Virol 1997 71 2947 2958 9060654
45. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. Portela A, Digard P, J Gen Virol 2002 83 723 734 11907320
46. Interaction of the influenza a virus nucleocapsid protein with the viral RNA polymerase potentiates unprimed viral RNA replication. Newcomb LL, Kuo RL, Ye Q, Jiang Y, Tao YJ, Krug RM, J Virol 2009 83 29 36 10.1128/JVI.02293-07 18945782
47. Influenza polymerase activity correlates with the strength of interaction between nucleoprotein and PB2 through the host-specific residue K/E627. Ng AK, Chan WH, Choi ST, Lam MK, Lau KF, Chan PK, Au SW, Fodor E, Shaw PC, PLoS ONE 2012 7 36415 10.1371/journal.pone.0036415 22570712
48. Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. Li Z, Watanabe T, Hatta M, Watanabe S, Nanbo A, Ozawa M, Kakugawa S, Shimojima M, Yamada S, Neumann G, Kawaoka Y, J Virol 2009 83 4153 4162 10.1128/JVI.02642-08 19225007
49. A single amino acid in the PB2 gene of the influenza A virus is a determinant of host range. Subbarao EK, London W, Murphy BR, J Virol 1993 67 1761 1764 8445709
50. Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue. Kuzuhara T, Kise D, Yoshida H, Horita T, Murazaki Y, Nishimura A, Echigo N, Utsunomiya H, Tsuge H, J Biol Chem 2009 284 6855 6860 10.1074/jbc.C800224200 19144639
51. Sequence in the influenza A virus nucleoprotein required for viral polymerase binding and RNA synthesis. Marklund JK, Ye Q, Dong J, Tao YJ, Krug RM, J Virol 2012 86 7292 7297 10.1128/JVI.00014-12 22532672
52. The Structure of Native Influenza Virion Ribonucleoproteins. Arranz R, Coloma R, Chichón J, Conesa JJ, Carrascosa JL, Valpuesta JM, Ortín J, Martln-Benito J, Science 2012 338 1634 1637 10.1126/science.1228172 23180776
53. Evolution of the nucleoprotein gene of influenza A virus. Gorman OT, Bean WJ, Kawaoka Y, Webster RG, J Virol 1990 64 1487 97 2319644
54. Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA subunit reveal the substrate binding site inside the catalytic center. Zhao C, Lou Z, Guo Y, Ma M, Chen Y, Liang S, Zhang L, Chen S, Li X, Liu Y, Bartlam M, Rao Z, J Virol 2009 83 9024 9030 10.1128/JVI.00911-09 19587036
55. Amino acid residues in the N-terminal region of the PA subunit of influenza A virus RNA polymerase play a critical role in protein stability, endonuclease activity, cap binding, and virion RNA promoter binding. Hara K, Schmidt FI, Crow M, Brownlee GG, J Virol 2006 80 7789 7798 10.1128/JVI.00600-06 16873236
56. Different De Novo Initiation Strategies Are Used by Influenza Virus RNA Polymerase on Its cRNA and Viral RNA Promoters during Viral RNA Replication. Deng T, Vreede FT, Brownlee GG, J. Virol 2006 80 2337 2348 10.1128/JVI.80.5.2337-2348.2006 16474140
57. Differential role of the influenza A virus polymerase PA subunit for vRNA and cRNA promoter binding. Maier H, Kashiwagi T, Hara K, Brownlee GG, Virology 2008 370 194 204 10.1016/j.virol.2007.08.029 17905403
58. Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding. Fetcher P, Mingay L, Sharps J, Chambers A, Fodor E, Brownlee GG, J Biol Chem 2003 278 20381 20388 10.1074/jbc.M300130200 12646557
59. The structural basis for cap binding by influenza virus polymerase subunit PB2. Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, Sehr P, Lewis J, Ruigrok RW, Ortin J, Hart DJ, Cusack S, Nat Struct Mol Bio 2008 15 500 506 10.1038/nsmb.1421
60. Residue 627 of PB2 is a determinant of cold sensitivity in RNA replication of avian influenza viruses. Massin P, van der Werf S, Naffakh N, J Virol 2001 75 5398 5404 10.1128/JVI.75.11.5398-5404.2001 11333924
61. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y, Virology 2004 320 258 266 10.1016/j.virol.2003.11.030 15016548
62. Host-range determinants on the PB2 protein of influenza A viruses control the interaction between the viral polymerase and nucleoprotein in human cells. Labadie K, Dos Santos Afonso E, Rameix-Welti MA, Van Der Werf S, Naffakh N, Virology 2007 362 271 282 10.1016/j.virol.2006.12.027 17270230
63. Host determinant residue lysine 627 lies on the surface of a discrete, folded domain of influenza virus polymerase PB2 subunit. Tarendeau F, Crepin T, Guilligay D, Ruigrok RW, Cusack S, Hart DJ, PLoS Pathog 2008 4 1000136 10.1371/journal.ppat.1000136 18769709
64. Characterization of influenza virus PB1 protein binding to viral RNA: two separate regions of the protein contribute to the interaction domain. González S, Ortin J, J Virol 1999 73 631 637 9847368
65. A 48-amino-acid region of influenza a virus PB1 protein is sufficient for complex formation with PA. Perez DR, Donis RO, J Virol 1995 69 6932 6939 7474111
66. Identification of two separate domains in the influenza virus PB1 protein involved in the interaction with the PB2 and PA subunits: a model for viral RNA polymerase structure. González S, Zürcher T, Ortin J, Nucleic Acids Res 1996 24 4456 4463 10.1093/nar/24.22.4456 8948635
67. Functional analysis of PA binding by influenza a virus PB1: effects on polymerase activity and viral infectivity. Perez DR, Donis RO, J Virol 2001 75 8127 8136 10.1128/JVI.75.17.8127-8136.2001 11483758
68. Crystal structure of the polymerase PAC-PB1Ncomplex from an avian influenza H5N1 virus. He X, Zhou J, Bartlam M, Zhang R, Ma J, Lou Z, Li X, Li J, Joachimiak A, Zeng Z, Ge R, Rao Z, Liu Y, Nature 2008 454 1123 1126 10.1038/nature07120 18615018
69. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. Sugiyama K, Obayashi E, Kawaguchi A, Suzuki Y, Tame JR, Nagata K, Park SY, EMBO J 2009 28 1803 1811 10.1038/emboj.2009.138 19461581
70. Emerging antiviral targets for influenza A virus. Krug RM, Aramini JM, Trends Pharmalcol Sci 2009 30 269 277 10.1016/j.tips.2009.03.002
71. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M, PLoS ONE 2009 4 7517 10.1371/journal.pone.0007517 19841738
72. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A, Nagata K, Tame JR, Park SY, Nature 2008 454 1127 1131 10.1038/nature07225 18660801
73. Peptide-mediated interference with influenza A virus polymerase. Ghanem A, Mayer D, Chase G, Tegge W, Frank R, Kochs G, García-Sastre A, Schwemmel M, J Virol 2007 81 7801 7804 10.1128/JVI.00724-07 17494067
74. In vitro and in vivo activities of anti-influenza virus compound T-705. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Shiraki K, Antimicrob Agents Ch 2002 46 977 981 10.1128/AAC.46.4.977-981.2002
75. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL, Antivir Res 2013 100 446 454 10.1016/j.antiviral.2013.09.015 24084488
76. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Gunther S, Antivir Res 2014 105 17 21 24583123
77. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J, PloS ONE 2013 8 68347 10.1371/journal.pone.0068347 23874596
78. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A (H1N1) viruses. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI Gubareva LV, Antimicrob. Agents Ch 2010 54 2517 2524 10.1128/AAC.01739-09
79. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y, Proc Natl Acad Sci USA 2010 107 882 887 10.1073/pnas.0909603107 20080770
80. Pharmacological effects of favipiravir, an anti-influenza viral drug. Takahashi K, Smee DF, Shiraki K, Kawaoka Y, Furuta Y, J Med Pharm Sci 2011 66 429 441
81. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Menéndez-Arias L, Álvarez M, Pacheco B, Curr Opin Virol 2014 8 1 9
82. Nucleozin Targets Cytoplasmic Trafficking of Viral Ribonucleoprotein-Rab11 Complexes in Influenza A Virus Infection. Amorim MJ, Kao RY, Digard P, J Virol 2013 87 4694 4703 10.1128/JVI.03123-12 23408618
83. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, Lin-Chu SY, Chen YH, Wu CY, Lai MM, Cheng WC, Wu YT, Tsai MD, Cheng YS, Wong CH, Proc Natl Acad Sci USA 2010 107 19151 19156 10.1073/pnas.1013592107 20974907
84. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Gerritz SW, Cianci C, Kim S, Pearce BC, Meminie C, Discotto L, McAuliffe B, Minassian BF, Shi S, Zhu S, Zhai W, Pendri A, Li G, Poss MA, Edavettal S, McDonnell PA, Lewis HA, Maskos K, Mörtl M, Kiefersauer R, Steinbacher S, Baldwin ET, Metzler W, Bryson J, Healy MD, Philip T, Zoeckler M, Scartman R, Sinz M, Leyva-Grado VH, et al. Proc Natl Acad Sci USA 2011 108 15366 15371 10.1073/pnas.1107906108 21896751
85. Influenza nucleoprotein: promising target for antiviral chemotherapy. Cianci C, Gerritz SW, Deminie C, Krystal M, Antiviral Chem Chemother 2013 23 77 91
86. Mycalamide A, an antiviral compound from a New Zealand sponge of the genus Mycale. Perry NB, Blunt JW, Munro MH, Pannell LK, J Am Chem Soc 1988 110 4850 4851 10.1021/ja00222a067
87. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Hagiwara K, Kondoh Y, Ueda A, Yamada K, Goto H, Watanabe T, Nakata T, Osada H, Aida Y, Biochem Bioph Res Co 2010 394 721 727 10.1016/j.bbrc.2010.03.058
88. The NPI-1/NPI-3 (karyopherin alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal. Wang P, Palese P, O'Neill RE, J Virol 1997 71 1850 1856 9032315
89. An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Cros JF, García-Sastre A, Palese P, Traffic 2005 6 205 213 10.1111/j.1600-0854.2005.00263.x 15702989
90. Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and enhances viral RNA synthesis. Momose F, Basler CF, O'Neill RE, Iwamatsu A, Palese P, Nagata K, J Virol 2001 75 1899 908 10.1128/JVI.75.4.1899-1908.2001 11160689
91. The cellular RNA helicase UAP56 is required for prevention of double-stranded RNA formation during influenza A virus infection. Wisskirchen C, Ludersdorfer TH, Müller DA, Moritz E, Pavlovic J, J Virol 2011 85 8646 8655 10.1128/JVI.02559-10 21680511
92. Replication-coupled and host factor-mediated encapsidation of the influenza virus genome by viral nucleoprotein. Kawaguchi A, Momose F, Nagata K, J Virol 2011 85 6197 6204 10.1128/JVI.00277-11 21507964
93. Structure-based discovery of the novel antiviral properties of Naproxen against the nucleoprotein of influenza A virus. Lejal N, Tarus B, Bouguyon E, Chenevas S, Bertho N, Delmas B, Ruigrok RW, Di Primo C, Slama-Schwok A, Antimicrob Agents Ch 2013 57 2231 2242 10.1128/AAC.02335-12
94. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Muratore G, Goracci L, Mercorelli B, Foeglein Á Digard P, Cruciani G, Palù G, Loregian A, Proc Natl Acad Sci USA 2012 109 6247 6252 10.1073/pnas.1119817109 22474359
95. Structure-based discovery of anti-influenza virus A compounds among medicines. Fukuoka M, Minakuchi M, Kawaguchi A, Nagata K, Kamatari YO, Kuwata K, Biochim Biophys Acta 1820 2012 90 95
96. NMR identification of anti-influenza lead compound targeting at PACsubunit of H5N1 polymerase. Li L, Chang SH, Xiang JF, Li Q, Liang HH, Tang YL, Liu YF, Chinese Chem Lett 2012 23 89 92 10.1016/j.cclet.2011.09.006
97. Anti-influenza Activity of C60Fullerene Derivatives. Shoji M, Takahashi E, Hatakeyama D, Iwai Y, Morita Y, Shirayama R, Echigo N, Kido H, Nakamura S, Mashino T, Okutani T, Kuzuhara T, PLoS ONE 2013 8 66337 10.1371/journal.pone.0066337 23785493
98. New 7-Methylguanine Derivatives Targeting the Influenza Polymerase PB2 Cap-Binding Domain. Pautus S, Sehr P, Lewis J, Fortuné A, Wolkerstorfer A, Szolar O, Guilligay D, Lunardi T, Décout J, Cusack S, J Med Chem 2013 56 8915 8930 10.1021/jm401369y 24134208